Stanley Druckenmiller Reata Pharmaceuticals Inc Transaction History

Duquesne Family Office LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$24.12 - $39.6 $8.38 Million - $13.8 Million	-347,267 Reduced 85.48%	58,997 $1.93 Million
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $7.4 Million - $32 Million	-288,769 Reduced 41.55%	406,264 $10.7 Million
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $5.77 Million - $8.25 Million	57,689 Added 9.05%	695,033 $69.9 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $8.81 Million - $17 Million	-112,553 Reduced 15.01%	637,344 $90.2 Million
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $21 Million - $38 Million	205,996 Added 37.87%	749,897 $92.7 Million
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $1.03 Million - $1.8 Million	11,023 Added 2.07%	543,901 $53 Million
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $126,300 - $176,560	1,000 Added 0.19%	532,878 $83.1 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $13.1 Million - $26.1 Million	105,159 Added 24.64%	531,878 $76.8 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $18.9 Million - $55.2 Million	253,434 Added 146.25%	426,719 $87.2 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $12.3 Million - $16.6 Million	173,285 New	173,285 $13.9 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.